Gorlin syndrome is a rare inherited condition that makes a person unusually prone to developing certain tumors, most notably a type of skin cancer called basal cell carcinoma, along with jaw cysts and a range of skeletal differences. It affects roughly 1 in 40,000 to 60,000 people. Also called nevoid basal cell carcinoma syndrome, the condition is present from birth, though many of its features don’t become apparent until childhood or early adulthood.
What Causes Gorlin Syndrome
Gorlin syndrome is caused by a mutation in a gene called PTCH1, which normally acts as a brake on cell growth. When one copy of this gene is faulty, that brake doesn’t work properly, allowing certain cells to multiply in ways they shouldn’t. PTCH1 mutations account for 50 to 85 percent of cases. A smaller number of cases involve mutations in another gene called SUFU, or in genes that haven’t yet been identified. The specific gene involved matters, because it influences which features of the syndrome are most likely to appear and how monitoring should be tailored.
The condition follows an autosomal dominant inheritance pattern, meaning you only need one altered copy of the gene (from one parent) to be affected. Most people with Gorlin syndrome inherited the mutation from a parent who also has it. In some cases, though, the mutation arises for the first time in a person with no family history.
Skin Cancer at an Early Age
The hallmark of Gorlin syndrome is the development of basal cell carcinomas, the most common type of skin cancer. In the general population, these cancers typically show up in older adults after decades of sun exposure. In Gorlin syndrome, they can appear as early as the teenage years or even childhood, and people often develop dozens or even hundreds over their lifetime. They tend to appear on the face, chest, and back, but can show up anywhere on the body.
Because these cancers grow slowly and rarely spread, they’re not usually life-threatening on their own. But the sheer number of them creates a significant burden. Repeated surgical removal can lead to scarring, and managing new growths becomes a lifelong process. Radiation therapy, a common treatment for basal cell carcinoma in the general population, is typically avoided in Gorlin syndrome patients because it can actually trigger the development of more skin cancers in the treated area.
Jaw Cysts
About 75 percent of people with Gorlin syndrome develop a specific type of jaw cyst called an odontogenic keratocyst. These cysts form in the jawbone, often near the roots of teeth, and can cause pain, swelling, or displacement of teeth as they grow. They tend to first appear in childhood, with the highest frequency in the teens and twenties.
These cysts are benign, but they have a stubborn tendency to come back after removal. Many people with Gorlin syndrome undergo multiple jaw surgeries over the years. Routine dental X-rays (orthopantomograms) are a key part of monitoring, typically starting around age 8 for those with PTCH1 mutations, so cysts can be caught and treated before they cause significant damage.
Palmar and Plantar Pits
One of the more distinctive physical signs of Gorlin syndrome is the appearance of tiny pits on the palms of the hands and soles of the feet. These look like small punctate depressions in the skin, typically 2 to 3 mm across and 1 to 3 mm deep. They’re flesh-colored, pink, or reddish, and they’re caused by the absence of the outermost protective layer of skin in those spots.
These pits develop gradually. Between 30 and 65 percent of patients have them by age 10, and that number rises to 85 percent by age 20. Having three or more palmar pits is considered a major diagnostic criterion for the syndrome, making them a useful clinical clue, especially in younger patients before other features have appeared.
Medulloblastoma Risk in Children
A small but important subset of children with Gorlin syndrome are at risk for medulloblastoma, a type of brain tumor that typically develops in early childhood. The risk depends heavily on which gene is involved. For children with PTCH1 mutations, the risk is low, under 2 percent. For those with SUFU mutations, the risk is up to 20 times higher, making early and frequent brain imaging essential.
Children with SUFU mutations are generally monitored with brain MRIs every 3 to 4 months during the first three years of life, then every 6 months until age 5. For children with PTCH1 mutations, brain imaging is only recommended if symptoms or neurological signs appear. This distinction underscores why genetic testing to identify the specific mutation matters so much for guiding care.
Ongoing Monitoring
Living with Gorlin syndrome means committing to a schedule of regular screenings tailored to your specific genetic variant. For skin checks, people with PTCH1 mutations typically begin annual dermatologic exams at age 10, while those with SUFU mutations start around age 20, since their skin cancer risk tends to emerge later. Jaw cyst screening with dental X-rays starts at age 8 for PTCH1 carriers and can be spaced out to every two or three years if no cysts are found, particularly after age 30.
Later in life, periodic brain MRIs every 3 to 5 years starting around age 30 are recommended to screen for meningiomas, a type of slow-growing brain tumor that can develop in adults with either genetic variant. Sun protection is also emphasized throughout life, since UV exposure accelerates the development of basal cell carcinomas in people who are already highly susceptible.
Life Expectancy and Outlook
Gorlin syndrome does reduce life expectancy compared to the general population, but the gap has narrowed considerably. One study found that average life expectancy for people with the syndrome was 73.4 years, compared to 80 years in the general population. Among several hereditary cancer-predisposing conditions studied, Gorlin syndrome had the longest life expectancy by a significant margin.
Importantly, people diagnosed in more recent decades, after structured genetic registries and surveillance programs were established, showed an 11-year increase in survival compared to those diagnosed before 1990. In recent years, life expectancy for people with Gorlin syndrome has approached that of the general population. This improvement reflects the power of early detection and consistent monitoring: when tumors and cysts are caught early and managed proactively, the condition becomes far more manageable than it once was.